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ABSTRACT 
Chronic hepatitis, morbidity and mortality of the patients and their children: 
The spread of Hepatitis C Virus (HCV) infection started in Sweden in the end of the 1960s 
with a culmination in the 1970s, most likely due to increased injection drug use. Mandatory 
notification of acute and chronic HCV infection in Sweden started in 1990. The estimated 
prevalence of viremic HCV infection in Sweden is 35,000- 45,000. Even though the 
prevalence is estimated to decrease during the next decade it is believed that the disease 
burden of HCV-related cirrhosis and HCC will increase. HCV is a global health problem with 
world prevalence of viremic HCV infection assessed to be 118.9 million. HCV infection has 
a quiescent progression where most individuals have only mild symptoms until 
decompensated cirrhosis. Approximately 5-30% patients develop cirrhosis in 20 to 30 years. 
The natural history of HCV infection in pregnancy and in infants is not well studied.  
The aim of this thesis was to study morbidity and mortality of individuals infected with HCV 
and/or B virus and in children of HCV infected mothers.  
In paper I the standardized incidence ratios (SIR) for hepatocellular cancer (HCC) were 
studied in individuals notified with HBV and HBV-HCV dual infection. In the HBV cohort 
(n=9,646), individuals infected with HBV in 40-49 years had 47 times increased risk of 
developing HCC compared with general population. In the HBV-HCV cohort (n=1,697), 
individuals with co-infection for 20-29 years had 34 times increased risk of developing HCC. 
This established the excessive risk of developing HCC in individuals with HBV and in those 
co-infected with HBV and HCV compared with the general population. Mortality and cause 
of death was studied in paper II. The standardized mortality ratio (SMR) demonstrated a 6 
times excess mortality in the HCV cohort (n=34,235) compared with the general population, 
and 36 times excess mortality from liver disease. Deaths from illicit drugs and external 
reasons were common in young adults. In paper III the odd ratio (OR) for the outcome of 
pregnancy of HCV infected mothers, compared with mothers in the general population 
Mothers with HCV infection (n=9,599) had increased risk for several adverse pregnancy 
outcomes. They had 7 times excessive risk of their pregnancy terminating in stillbirth and 
almost two times increased risk for late neonatal death. Paper IV, demonstrated excessive 
mortality in children (n=19,097) of mothers (n=9,599) with HCV infection compared with 
the general population. From 1 to 4 weeks, the adjusted hazard ratio (HR) was 2.26 and from 
1 to 6 months the HR was 2.63. From age 15 to 20 years of age HR was 2.50 and from year 
20 and onward the HR was 3.16.  
To conclude: HBV and HVB-HCV infected individuals have an excessive risk of developing 
HCC. Drug related mortality in the HCV-cohort was high. Liver related mortality was high in 
all cohorts. Mothers with HCV are in risk of adverse outcome of pregnancy. Children of 
mothers with HCV infection have an increased risk of dying in the perinatal period, within 6 
months of living or after their teenage years.  
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1 INTRODUCTION 
1.1 HISTORICAL ASPECTS OF HEPATITIS C VIRUS INFECTION 
Jaundice has been described since the time of the old testament and then later by Hippocrates 
in his writings 400 BCE (1). It came apparent when hepatitis B virus (HBV) and hepatitis A 
virus (HAV) were discovered in the 1970s, that an unknown hepatitis, mostly observed after 
blood transfusion, existed. In the beginning it was called Transfusion Associated Hepatitis. 
This new hepatitis was without the usual serological markers of HAV and HBV, and was 
eventually called non-A non-B hepatitis (NANBH) (2). This sporadically occurring hepatitis 
proved to have a prolonged, quiescent course, progressing to a chronic hepatitis and liver 
cirrhosis (3). Finally, identification of the hepatitis C virus (HCV) was successful in 1989 (4, 
5). The subsequent development of diagnostic tests showed that more than 90% of NANBH 
was caused by HCV (4, 6, 7). Most of the cases seemed to develop into chronic infection and 
gradually, it became apparent that the chronic HCV infection was on a global scale (8). 
1.2 HEPATITIS C VIROLOGY 
HCV is a small sphere formed virus, approximately 50-80 nm in diameter (9). The virus 
belongs to the Flaviviridae family and contains a single-stranded positive-sense ribonucleic 
acid (RNA) genome of 9600 nucleotides (5) (10). There are highly conserved 5’ and 3’ 
untranslated regions flanking an approximately 9000 nucleotide single open reading frame 
(ORF). The ORF encodes a large polyprotein of about 3000 amino acids (11). The protein 
undergoes posttranslational processing by host and viral proteases to form numerous 
structural and nonstructural protein and enzymes of the virus. The N terminus encodes the 
core protein (C), followed by two glycoprotein domains, the envelope E1 and E2, and the 
pore protein P7 (between the structural proteins and nonstructural proteins). Downstream to 
this region are the genes encoding nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A and 
NS5B. The nonstructural proteins are involved in the viral replication and packaging of the 
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viral genome in to capsids formed out of the structural proteins. The organization of the 
genome is illustrated in figure one (12). 
 
Figure 1. HCV genome architecture and the targets of Direct Acting Antiviral therapy.  
 
The virus produces between 1011 and 1013 virions per day and the halftime is only few hours 
(13, 14). The HCV strains are now classified into seven genotypes (6 that are clinically 
relevant) and currently 67 subtypes (15, 16), with individual geographic distribution and 
sensitivity to interferon-based therapy (17, 18). Despite the difference in the nucleotide 
sequence among the genotypes, all currently known HCV genotypes are hepatotropic and 
pathogenic. 
1.3 DIAGNOSIS OF HEPATITIS C VIRUS INFECTION 
HCV infection is characterized by the appearance of the following markers in chronological 
sequence HCV RNA, HCV antigens and subsequently HCV antibodies.  
1.3.1 Serological Assays 
Diagnostic methods for HCV became available in 1990. Antibodies to HCV can be detected 
using several assays, the standard immunoassays are usually performed in laboratories and 
rapid immunoassays can be performed on test location.  
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Standard immunoassays are based on recognition of specific anti-HCV antibodies in serum or 
plasma. These antibodies are linked to various methods for the signaling of a positive test: 
enzymatic reaction (EIA, also called enzyme-linked immunosorbent assays or ELISA and 
chemo luminescence assays). These methods have improved through time. The advances in 
assay performance, particularly of the EIAs, have been termed as “generations” of the assays. 
These advances are based on the use of different antigens to detect the HCV antibodies. By 
every generation, the window from infection until detection became reduced. The more 
specific second generation was established 1991 and like the third generation, these tests 
detect human antibodies against HCV antigens from the core, NS3, NS4, and NS5 proteins. 
The tests become positive about eight weeks after exposure. In most patients, seroconverting 
occurs between two and six months after exposure to the virus (19-21). The currently used 
EIAs detect HCV–antibodies with high sensitivity and specificity (22). Antibody tests cannot 
distinguish between persons with ongoing HCV infection and those with a resolved infection. 
Anti-HCV cannot be detected in those who are recently infected and have not yet developed 
anti-HCV antibodies. In immune compromised patients, such as patients with advanced 
human immunodeficiency virus (HIV) infection or on hemodialysis, anti-HCV may not be 
detectable despite the presence of HCV infection. In these groups of patients, measurement of 
HCR RNA is required to confirm the diagnosis (23, 24).  
Rapid immunoassay tests have been developed to provide opportunities for HCV testing 
outside of clinical settings. 
To confirm the positive anti-HCV antibodies, the more specific recombinant immunoblot 
assay (RIBA) has proved to be useful. This test is also based on the detection of HCV 
antibodies and is not correlated to infectivity. To further narrow the window of infection and 
to detect and quantify an ongoing infection, quantitative enzyme immunoassays to detect 
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HCV core antigen were developed (25-27). These HCV-core antigen tests correlate well to 
quantitative HCV RNA analyses but are less sensitive for low levels of HCV-RNA.  
 
Figure 2. The serological markers of chronic HCV infection, ALT: Alanine Aminotransferase 
 
1.3.2 Molecular testing of Hepatitis C 
Several methods can be used to detect and measure HCV RNA: Polymerase chain reaction 
(PCR) based methods, transcription mediated amplification (TMA) and branched DNA assay 
(28). HCV RNA can be detected in the plasma as early as one week after the time of 
infection. The levels of HCV RNA can fluctuate around the time of the seroconversion (29). 
Recently, fully automated real-time PCR or real-time TMA assays (28, 30) have emerged. 
The newer methods are more sensitive than the previous ones (26). The lower limit of 
detection of HCV RNA is 10-20 IU/ml and slightly lower for TMA. The range of variation of 
detection more than ±0.2 Log 10 IU/ ml is considered as a significant difference (26). The 
unit IU/ml is now used instead of the earlier non-standardized unit copies/ml (31).  
Viral sequence analysis has been performed to identify the genome of HCV. Its strains are 
classified into seven genotypes (1–7, first 6 have clinical importance) and large number of 
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subtypes (15). Currently, different genotypes require different treatment regimen and affect 
the duration of treatment. Furthermore, the genotype (and other factors such as previous 
treatment attempts, resistance to NS5A inhibitors and stage of fibrosis) is of importance when 
predicting the result and resistance to therapy.  
1.4 EPIDEMIOLOGY  
1.4.1 The global burden of Hepatitis C virus infection 
The major burden of HCV is related to the sequel of chronic infection. HCV infection is an 
important health problem. The prevalence reports vary depending on regions, time periods 
and if prevalence of anti-HCV or HCV RNA were used for the assessment.  
According to available data, the estimated world prevalence was reported to be from 2.2 to 
3.0% (130-184 million people) (32-34). A recent study, including published data from 138 
countries between years 2000 and 2015, assessed the global prevalence of anti-HCV positive 
individuals to be 2.5% (177 millions). The viremic rate was estimated to 67%, corresponding 
to approximately 118.9 million individuals being HCV RNA positive (33). There is large 
variability of prevalence in different regions. The highest prevalence is reported from Africa, 
Asia (0.9-6%) and Eastern Europe (3.1%) and the lowest from industrialized nations in North 
America, Northern and Western Europe, and Australia (0.5-1.8%) (33, 35, 36). There has 
been some change over time of the regional estimates, but according to the Global Burden of 
Disease (GBD) for HCV report of year 2004, the estimates have remained similar since the 
1990's (37). The more recent data from Petruzziello et al. observed a decrease of the 
prevalence in industrialized countries and a considerable increase in low income areas such as 
Central Africa and Central Asia compared to the period 1990 to 2005 (33).  
The most prevalent HCV genotype worldwide is genotype 1 (49.1%), followed by genotype 3 
(17.9%), 4 (16.8%) and 2 (11.0%) (33). The remaining 5% were genotypes 5 and 6. In 
Europe and America genotype 1 is the most prevalent. In Asia genotype 1 was the most 
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prevalent and in Africa genotype 4 and 1 was the most common genotype. In North and 
South America and in Australia genotype 1 and 3 dominated. While genotypes 1 and 3 are 
common worldwide, the largest proportion of genotypes 4 and 5 seem to be in lower-income 
countries (33). 
In people who inject drugs (PWID), genotype 1 is the most prevalent as well. In Europe, 
genotypes 1, 3 and 4 are highly prevalent among PWID, in Asia genotype 2 and 6, and in 
Africa genotype 1a and 4 are the most observed. Overall, when comparing with the general 
population, there is a lower prevalence of genotype 1b in the PWID population and higher 
prevalence of genotype 1a and 3 (38). 
1.4.2 Route of transmission 
In the years leading to 1992, the most important source of infection was contaminated blood 
and blood products and IDU. Transfusion of contaminated (HCV-RNA positive) blood, or 
blood products, is highly infectious, and 98% of recipients get infected. Even low viral levels 
(HCV-RNA <100IU/ML) are sufficient (39, 40). Since routine blood donor screening for anti 
HCV started in the early 1990s in many countries (in Sweden during 1991), the transmission 
via contaminated blood has decreased drastically and is now virtually eliminated (41). 
Transmission via unsafe injections in health care is less frequent in industrialized countries, 
but is still a major problem in other parts of the world (Middle East, South-East Asia and 
Western Pacific) where the cause is re-using of contaminated needles/syringes and blood 
products in various procedures (32, 42). One of the largest known outbreaks was the use of 
contaminated injections in Egypt until the year 1986, in treating schistosomiasis (43). In 1993 
and early 1994 patients in Sweden were treated with contaminated immunoglobulin 
preparation which resulted in increased HCV transmission (44). It has been estimated that 2 
million patients get infected annually from contaminated health care injections (45). Organ 
donation has been another known transmission route (46). Currently IDU is the most 
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common route of transmission. It is estimated that more than 67% of all PWID get infected 
with HCV (47, 48). PWID  have the highest ratio of new HCV infections worldwide 
(49).Transmission via sexual activity is a controversial issue but the overall risk seems to be 
very low (50). The risk of vertical transmission is the most important route of infection 
among children (51). Vertical transmission is thought to occur in late pregnancy, at delivery 
or in the postnatal period (51, 52). In the majority of infected infants, HCV RNA levels only 
became detectable several weeks after birth, suggesting perinatal infection (either late intra 
uterine or during birth) (53-55). A recent meta-analysis of Benova et al. showed risk of 5.8% 
in HIV negative RNA positive mothers (56). However, in antibody-positive /RNA-negative 
mothers, the risk was negligible. The risk in HIV positive and RNA positive mothers was 
10.8% (56). HCV viremia in the mother seems to be conditional for vertical transmission. 
The risk of transmission increases with high viral load. Other factors that have been reported 
to influence the transmission rate are: female gender of infant, prolonged rupture of 
membranes, and fetal scalp monitoring (57-59). Caesarian delivery is currently not 
recommended as a risk-reducing intervention (60, 61). There is no evidence of HCV 
transmission from mother to infant through breast feeding and therefore it is not 
contraindicated (60). There are no approved antiviral therapies against HCV for use during 
pregnancy (62). 
1.4.3 Hepatitis C virus infection in Sweden  
The spread of non-A, non-B hepatitis started in the end of the 1960s with a culmination in the 
1970s, most likely due to increased IDU (63). Mandatory notification of acute and chronic 
HCV infection in Sweden started in 1990. All clinicians and laboratories that diagnose HCV 
infection are obliged to notify the infection to the Public Health Agency of Sweden (PHAS). 
Screening of HCV infection in blood donors started in 1991. In 2007, all individuals who 
during childhood and before 1992 underwent heart surgery, cancer therapy or were admitted 
to the neonatology department and subsequently got blood transfusion were recommended to 
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get tested for HCV infection. In 2010, women who had received postpartum transfusions 
were also included in the screening recommendations (64). This resulted in identification of 
about 600 anti-HCV positive individuals (64, 65).  
There are currently 9,9 million residents in Sweden. Approximately 2,000 cases of HCV 
infection are reported to the PHAS each year (65). In a recently published report from the 
PHAS, a total of 64,200 cases of anti-HCV were reported to the agency from 1990 until the 
beginning of the year 2016 (65). Of those, 5,000 individuals had wrong identification 
numbers, 15,800 were deceased, 1,300 had emigrated and 200 individuals were missing. The 
PHAS made the conservative estimation that 15% are spontaneously cleared from the virus 
(earlier epidemiologic studies have estimated the viremic rate at 77% thus 23% cleared the 
virus) and that 5,000 individuals had cleared the virus after therapy (65-67). This results in a 
total of 37,500 individuals with viremic HCV in Sweden. When assuming that approximately 
20% of HCV positive individuals are undiagnosed the prevalence of chronic viremic HCV is 
estimated to  35,000- 45,000 (0.35%-0.45%) (65).  
Nearly 70% of the individuals notified with HCV infection are men and the majority (80%) 
was born in 1950 or later. Approximately 90% of them originate from the Nordic countries 
(35, 66). Information regarding suspected route of transmission is required in the clinical 
notifications. The route of transmission has been found to be IDU in approximately 65% 
cases, unknown in 26% of cases. Recent study on inpatient care of the Swedish HCV cohort 
revealed that large proportion of the unknown transmission routes was probably IDU related, 
since many of these patients had prior psychiatric diagnose related to drug abuse (63). Only 
2% of cases were sexual transmission and 6% of cases were transfusion of blood/blood 
products. Other less frequent infection routes are vertical infection, occupational and 
nosocomial (35). Since the blood-donor screening started, the transmission via blood-
products has decreased dramatically (35). Lidman et al established that 90% of injection drug 
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users in Sweden were anti-HCV positive by the age of 30 and furthermore within 2 years 
after first injecting drugs almost 50% had antibodies for HCV (47). In Sweden, 45% of HCV 
infected individuals had genotype 1, 19% genotype 2, 34% are genotype 3 and 2% genotype 
4, (67, 68).  
According to the Medical Product Agency, approximately 1100 individuals have been treated 
for HCV in Sweden in recent years, but this figure has increased since introduction of direct 
acting antivirals (DAAs) in 2014. Since the millennium, 10,000- 15,000 individuals have 
been treated in total (63, 65). Previously in the IFN era, cure rate of 40-50% was seen, 
resulting in estimation of a minimum 5,000 cured persons(63).  
In the light of new the treatment era, a study based on a predictive model estimated that 
doubling the number of patients treated with DAAs is needed to reduce liver related deaths by 
70% and viremic cases by 55% in Sweden (67). The HCV-related disease burden in Sweden 
is expected to increase in the next decade primarily because of an aging cohort and the long 
lag time, unless increased treatment and cure rate (63, 67, 69).  
HCV infection has become one of the leading indications of liver transplantation in Sweden. 
Among patients that undergo liver transplantation, HCV infection is the underlying cause in 
approximately 25% of cases (70). The Swedish Organ Transplant Database, Scandia 
transplant, reported that year 2011, 156 liver transplants were performed in Sweden, of whom 
22% were anti-HCV-positive (67, 71). In years 1997-2013 a total of 590 patients underwent 
liver transplantation on the basis of chronic HCV infection (69).  
1.5 CLINICAL MANIFESTATION OF HEPATITIS C VIRUS INFECTION 
Following HCV infection, HCV-RNA can be detected in the serum about one week after 
infection (20, 72-75). Several weeks later, the liver related enzymes rise noticeable and peak 
more than 10-fold higher than the upper limit of the enzyme (20, 74, 76). The majority of 
infected persons have no or few symptoms and only about 20% develop symptoms of acute 
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hepatitis. The time from exposure to jaundice is about 7 weeks (75, 77, 78). HCV-related 
fulminant hepatitis is rare but the risk might be increased in concomitant chronic HBV 
infection (79-81). Frequency of development of chronic HCV is 75% to 85%, defined as 
repeated detection of HCV RNA in the serum of the patient for more than 6 months (82, 83). 
During chronic HCV infection, viral levels of HCV remain generally constant, although 
fluctuations can occur (84). Advanced age at infection, male gender, African American race, 
immunosuppressive state, specific HLA types, reduced innate immune response and to some 
extent genotypes, are factors that are associated with persistence of HCV virus (82, 85-88). 
Another host factor that may influence the ability to clear the virus is the polymorphism of a 
chromosomal locus close to interleukin-28B (IL28B) (89, 90). The allele type C/C was 
associated with clearance rates of approximately 50-55% compared to 16-20 % of those with 
the more unfavorable allele type T/T (89). Other host factors such as symptom of acute 
infection, infection during childhood, female sex, presence of specific HLA types, high titers 
of HCV neutralizing antibodies and the presence of CD4 T-cell response are associated with 
higher likelihood of spontaneous clearance (85, 91-96) 
Although most patients have mild symptoms or are asymptomatic before culmination in end 
stage liver disease, some patients complain of generalized, nonspecific symptoms such as 
fatigue, nausea, anorexia, myalgia, arthralgia weakness and weight loss (97). The symptoms 
do not correlate to the viral load or level of liver fibrosis. They seem to be correlated to the 
awareness of the infection and appear to improve after successful treatment (98-100). 
Liver fibrosis begins at the portal area and extends as a bridge from one portal area to the next 
(101). With time, fibrosis can progress further with remodeling and encircles the liver lobule 
culminating in liver cirrhosis. Studies have shown variable rates of development of fibrosis 
and cirrhosis. Approximately 5-30% develops cirrhosis in 20 to 30 years. The estimation 
vary, possibly because of different study populations and due to referral bias in tertiary care 
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centers (102-104). Lower rates have been reported from community based studies (105). 
Estimates from retrospective studies have been higher than prospective studies. Studies of 
patients who presented clinically with chronic hepatitis tend to report a more aggressive 
course with a higher risk of cirrhosis development (103, 106, 107). Lower rates were reported 
in those of younger age at infection and in women (108-111). Several additional factors 
appear to be important determinants of prognosis such as ethnicity, alcohol use, obesity, and 
HBV or HIV co-infections. Baseline inflammation and fibrosis in liver biopsies or by 
noninvasive measurements is a good clinical predictor. Patients with mild inflammation on a 
liver biopsy had low annual risk, patients with moderate chronic hepatitis had approximately 
5% and patients with bridging fibrosis had approximately 10% annual risk of developing 
cirrhosis (102, 112, 113). Other associated factors that had negative impact are D-vitamin 
deficiency (114). Regular coffee consumption is associated with lower rate of disease 
progression (115). Liver histology is the best indicator to evaluate the grade of inflammation 
and the stage of fibrosis (102, 116). Non-invasive methods that evaluate the stiffness of the 
liver such as elastography have proved to be useful (117, 118).  
The most frequent complications associated with liver disease are ascites, variceal bleeding, 
encephalopathy and jaundice. Almost all patients who develop these complications have 
cirrhosis. The risk of developing hepatic decompensation is estimated at 3.9% per year in 
patient with compensated liver cirrhosis (119). Once complications of cirrhosis have 
occurred, liver transplant has been the only effective therapy to prevent liver-related 
mortality. With introduction of DAAs, patients with more advanced liver disease can now be 
treated and some patients have improved and been delisted from liver transplantation 
awaiting list, after successful therapy with DAAs (120).  
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1.5.1 Chronic hepatitis and Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh 
most common cancer in women worldwide. HCC is the second most common cancer related 
cause of death in men and the sixth leading cause of cancer death in women (121). There is a 
gradual yearly increase of HCC incidence rates and death rates in many parts of the world 
such as in central-Europe and North-America (122-124). The incidence is threefold in men 
compared to women (123). Furthermore, there seems to be a shift of age distribution to 
increased proportion in younger age groups of 45-60 years (125).  
The known HCC risk factors are chronic HBV and/or HCV infection and alcoholic liver 
disease (126). It occurs less frequently in nonalcoholic fatty liver disease, hemochromatosis, 
alpha1-antitrypsin deficiency, autoimmune hepatitis, porphyria and Wilson’s disease.  
The rate of developing HCC is associated with the underlying etiological factors, which have 
a great regional variability. Almost 75 % of global cases are due to underlying chronic HBV 
or HCV infection (127, 128). The 5-year incidence is 17-30 % in HCV infection and 10 % in 
HBV infection (126, 129). 
Although most cases of chronic HBV related HCC occur in patients who have already 
developed cirrhosis (85%), HCC can arise in the absence of advanced fibrosis (130). The risk 
of HCC in HBV infected individuals is greater in individuals with active replication and high 
viral load (131, 132). However, available data indicates that both treated patients and those 
that have serologically resolved their infection are still at risk of developing HCC (133). 
Thus, indicating probable oncogene activation by the HBV virus itself. Occult HBV infection 
with or without HCV infection might also be a risk factor in the development of HCC, either 
through accelerating development of cirrhosis or through hepatocellular transformation by 
oncogenic action. The significance of occult HBV infection in the pathogenesis of HCC is 
however still unresolved (134).  
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 Most studies on the risk of HCC in HBV infected individuals are performed in high endemic 
areas. Only a few adequate studies from Europe have determined the incidence HCC in 
chronic state of HBV infection. The incidence rate of HCC in Asian countries is higher than 
in low endemic countries especially in the context of cirrhosis (3.7 per 100 person-years 
compared to 0.2 per 100 person-years) (121). There are several co-risk factors that contribute 
to increased risk of developing HCC in HBV infected individuals such as male gender, older 
age, Asian or African origin, high levels of HBV replication, HBV genotype, duration of 
infection, co-infection with HCV/HIV/HDV, aflatoxin intake and alcohol consumption (125).  
HCC in HCV infection occurs almost exclusively in those with cirrhosis and HCV infection 
accounts for approximately one-third of HCC cases. According to earlier studies, HCV 
infection is associated with 15-20 fold increase in risk for HCC (125). A Swedish study 
demonstrated a 40-fold increase of the risk for HCC after more than 25 years with HCV 
infection (135). The yearly risk of developing HCC once cirrhosis has developed has varied 
from 1-8% percent (119, 125, 136). After 40 years of estimated infection, the risk of 
developing HCC was estimated to be approximately 7% (87, 119, 135, 137). The incidence 
and mortality rates of HCC are increasing in the developed countries (138). The incidence 
rates for HCC in Sweden have been reported to be gradually decreasing since the 1980’s. 
However, a recent Swedish study has demonstrated that primary liver cancers are 
underreported in Sweden, probably because due to fewer histological verified diagnoses in 
recent years (139). With the aging HCV cohort in Sweden, cirrhosis and HCC have become 
one of the leading causes of liver transplantation in Sweden (63, 65, 71). Risk factors for 
HCC in individuals with chronic HCV are male gender, co-infection with HBV or HIV, 
diabetes, obesity and alcohol consumption.  
Only few studies have been undertaken in low endemic areas on HBV and HCV co-infection 
and the risk of HCC. Earlier studies from high endemic areas have indicated that patients 
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with dual HBV and HCV infection may have a higher rate of HCC compared to patients with 
mono infection (140-144).  
It is recommended that patients at high risk of developing HCC should be included in local 
surveillance program (145). According to EASL-EORTC guidelines, high risk is defined as; 
cirrhotic patients with Child-Pugh stage A and B, and patients with stage C awaiting liver 
transplantation, non-cirrhotic HBV carriers with active hepatitis and patients who have family 
history of HCC (with variable evidence which depends on regions) and patients with chronic 
HCV infection and advanced fibrosis F3 (with variable evidence which depends regions) 
(145). For diagnosis of HCC, a 4-phase multi detector CT scan or dynamic contrast-enhanced 
MRI is required for non-invasive criteria to be applied according to EASL. While one 
imaging technique is required for nodules 1-2 cm in diameter, two different techniques are 
recommended in suboptimal settings. Nodules above 2 cm require at least one positive 
technique. Diagnosis of HCC should be based on the identification of the typical signs of 
HCC (arterial hyper vascularity and venous/late phase washout) (145). 
HCC is often diagnosed in advanced stage. The median survival ranges from approximately 
6-20 months after diagnosis (146). There are currently several treatment options available for 
HCC. Surgical resection and liver transplantation are considered potentially curative 
alternatives. Patients that are not eligible for these modalities are considered for therapy with 
radiofrequency ablation (RFA) and microwave ablation, percutaneous ethanol and acetic acid 
ablation, transarterial chemoembolization (TACE), cryoablation, radiation therapy and 
stereotactic radiotherapy. The systemic therapy presently available is molecular targeted 
therapy (Sorafenib). The treatment modality is determined by the extent of the tumor and on 
the severity of the underlying liver disease (145).  
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1.5.2  Hepatitis C virus infection and extrahepatic manifestations 
Extrahepatic manifestations are common in association with chronic HCV infection. It has 
been reported that almost 40% of the patients have one or more extrahepatic complications 
(147). They can be grouped into several categories:   
Hematological disorders: The association HCV infection and essential mixed 
cryoglobulinemia is established and a high percentage of these patients have a HCV infection 
(148). Some association between monoclonal gammopathies and HCV infection has been 
demonstrated and there seems to be an association between HCV- infection and B-cell non-
Hodgkin lymphoma (149). Thrombocytopenia and autoimmune hemolytic anemia have been 
associated with HCV infection (150).  
Dermatological: An association between porphyria cutanea tarda and HCV infection has 
been demonstrated in several studies (151). Leukocytoclastic vasculitis, lichen planus and 
necrolytic acral erythema have also been observed in association with HCV infection (147). 
Musculoskeletal manifestation: Rheumatoid like arthritis and oligo arthritis has been 
described in patients with chronic HCV infection (147).  
Autoimmune disorders: Autoantibodies are common in patients with chronic HCV infection 
although they often do not seem to have clinical significance (147). Autoimmune hepatitis 
indicated by expression of autoantibodies can cause a clinical dilemma when determining the 
primary cause of hepatitis (152).  
Renal disease: Glomerular disease (with or without cryoglobulinemia) has been described in 
association with chronic HCV infection (153).  
Endocrinology: HCV infection has been linked to diabetes mellitus in several studies (154). 
Thyroid disorders are common in patients with chronic HBV infection and was often a side 
effect of IFN based therapy (155). 
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Cardiovascular: HCV infection has been associated with adverse cerebral and cardiovascular 
events (156).  
Nervous System: A range of neurological diseases (stroke, myelitis, encephalomyelitis, and 
seizures), neuropsychiatric diseases (depression, cognitive dysfunction), peripheral 
neuropathies and myopathies have been associated with HCV infection (147, 157).  
1.5.3 Hepatitis C virus infection and mortality 
Survival is decreased in individuals with chronic HCV infection compared to the general 
population. Earlier studies mostly from high endemic areas have indicated that HCV infected 
patients are more likely to die at a younger age from drug related causes, liver related causes 
and from HCC (158-164). Even in individuals who have cleared the virus, there is an overall 
increased mortality mainly due to complications of drug abuse and liver related causes, 
indicating  that lifestyle factors are important causal factors (163, 165). However, mortality is 
also increased in HCV infected patients who do not have the concomitant risk factors such as 
drug use and alcohol overconsumption (103, 166).   
1.6 HEPATITIS C VIRUS INFECTION IN PREGNANCY AND BIRTH 
1.6.1 Hepatitis C virus infection and pregnancy 
The natural course of HCV infection during pregnancy is not well understood. The mother’s 
immune system must simultaneously develop tolerance to paternal alloantigen and sustain an 
active immunity against HCV to shield both the mother and the fetus from infection (167). 
The prevalence of anti-HCV in pregnant women varies among populations and regions, but 
does not seem to differ from the respective general populations (168-171). Prevalence in 
pregnant intravenous drug users is reported to be high (80-90%) (51).  
Acute HCV infection is a rare event during pregnancy (172). Studies have shown a highly 
significant increase of intrahepatic cholestasis of pregnancy (ICP) in anti-HCV positive 
women (173-175). A recent Swedish study has confirmed that HCV infection is more 
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prevalent in women with ICP (176). One explanation might be the inflammatory process 
triggered by HCV infection; another, might simply be because of misclassification of ICP in 
the case of HCV infected mothers.  
During pregnancy in mothers with chronic HCV infection, a reduction and even 
normalization in the mean alanine aminotransferase (ALT) has been reported during second 
and third trimester (177-179). HCV viral load seems to increase during pregnancy, usually 
reaching a peak during the third trimester (177, 179, 180). Exacerbation of chronic HCV 
infection and rebound increase in ALT levels and worsening of liver histopathology has been 
reported in the post-partum period as well as reduction of HCV plasma viral load (181-185).  
Several studies have assessed the relationship between HCV infections in the mother and the 
outcome of the pregnancy. The studies have conflicting results. Two studies demonstrate that 
the rate of cesarean section was higher than in the control group (171, 186). The high rate was 
explained by the local protocols for HCV infected mothers. A study from USA demonstrated 
that infants born to HCV-infected women were more likely to be small for gestational age, 
have low birth weight and were admitted more often to the intensive neonatology department 
for assisted ventilation compared to random non-HCV mothers and drug-using non-HCV 
mothers (187). A recent meta-analysis illustrated that an intrauterine fetal growth disturbance 
was directly associated with maternal HCV infection when adjusted for various co-factors 
including maternal age, parity, maternal smoking, alcohol abuse, drugs abuse, coinfection 
with HBV/HIV and preeclampsia (188). Another meta-analysis demonstrated that there was a 
significant positive association between a preterm birth and HCV infection (189). Natural 
Killer T (NKT) cells are important for clearance of HCV in acute infection (190). Hurtado 
and group established that placental HCV infection increases cytotoxicity of NKT cells (191). 
This could explain both the mechanism of prevention of vertical infection and the adverse 
birth outcomes in the HCV infected mothers, as the infection of the virus induces NKT 
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cytotoxicity which produces cytokines and stimulates the innate immune response in the 
mother and thus contributes to placental damage, intrauterine growth restriction, perinatal 
mortality and preterm labor. Mor G et al. have shown that a viral infection of the mother 
induces production of inflammatory cytokines such as Tumor Necrosis Factor (TNF)α, 
Interferon (INF)γ, Interleukin (IL)-12 and IL-6 and thus activates the maternal immune 
system and causes placental damage, fetal mortality and preterm birth (192). If this process 
does not terminate the birth it might sensitize the mother to other infections and promote 
inflammation in the fetus (193).  
Stillbirth is defined by ICD 10, as early fetal death from 22 weeks to 28 weeks of gestation 
and as late fetal death after 28 weeks of gestation. The rate of stillbirth in industrialized 
countries declined from 1940, but epidemiological studies have indicated that in recent years 
the decline has slowed down (194). There is a great variation within high income countries 
with low rate in for example Norway (2.2 stillbirths per 1000 births) and high rate in the 
United Kingdom (3.8 stillbirths per 1000 births) (195). In year 2015 there were 3.7 stillbirths 
/1000 births (died intrauterine or at birth) according to Statistics Sweden. This variation might 
indicate that a further reduction is possible, although it might also indicate a difference in 
reporting and registration of intrauterine deaths between countries (196, 197). There have 
been speculations about how further improvement in prevention of stillbirth could be 
possible. Common causes of stillbirth are congenital abnormality of the infant and placenta 
related causes (lesions, abruptions) (198). Factors associated with infection and inflammation 
are also common causes for stillbirths (195). Both bacteria and viruses have been implicated 
(193). Other known risk factors are ethnic origin and socioeconomic status. Studies have 
shown that populations of different ethnicity within high-income countries have significantly 
higher ratio of stillbirth (199-204). Less formal education (<10 years) was associated with 
increased odds of stillbirth (205). Maternal obesity, smoking and advanced age was 
associated with increased rate of stillbirth (205, 206). Alcohol and illicit drug use during 
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pregnancy are also documented risk factors (205, 207). Drug abuse is associated with the 
doubling of the risk of stillbirth (205). Primiparity, advanced maternal age and high BMI at 
birth are important risk factors for stillbirth (208-210). In 30- 60% of cases the causes  remain 
unknown (211). In a Canadian observational study from 2004, intrauterine death was 
observed in 3.4 % of 145 mothers with HCV infection (212). The impact of HCV infection 
on stillbirth is still relatively unknown. 
1.6.2 Hepatitis C virus infection and infants 
During the first year of life, serologic positivity for anti-HCV in the child may represent 
passively transferred maternal antibodies. The antibodies seem to clear in 95% of infants by 
12 months of age. Therefore most guidelines recommend anti-HCV testing after more than 
12 months or the use of HCV RNA analyses. Perinatally acquired HCV infection becomes 
chronic in approximately 80% of cases (59, 213-215). Spontaneous clearance seems to occur 
predominately in early stages of infection at a younger age and in children with normal ALT 
levels (215). Almost all children who remain viremic after two years of age have chronic 
hepatitis (214, 216, 217). Pediatric HCV infection most often presents with mild liver disease 
and advanced liver disease is uncommon (218).  
1.6.3 Hepatitis C virus infection and therapy 
The aim of antiviral therapy is to eradicate HCV and prevent the development of advanced 
liver cirrhosis and its complications. This is attained by the achievement of sustained 
virologic response (SVR). SVR is defined by the absence of HCV RNA at 12-24 weeks after 
the end of treatment (219). The positive predictive value of SVR at week 12 is 99% chance of 
cure (219, 220). Eradication of the virus halts the progress of fibrosis in the liver and 
improves the liver histology and the general outcome of the patient (104, 221-224). 
Historically recombinant IFN- alfa was introduced in 1986 to treat patients with NANB 
hepatitis (225). Partial effectiveness was noticed and only few achieved SVR. In the late 
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1990’s, Ribavirin (RBV) was added to the regime and SVR increased to approximately 34% 
after 24 weeks of treatment, and 42% when prolonging therapy to 48 weeks (226, 227). The 
next step was prolonging the half-life of IFN by pegylation (adding a polyethylenglykol 
molecule), which improved the virologic response rates and reduced the injection frequency. 
Weekly injections of long-acting pegylated (PEG) IFN alone for 48 weeks induced SVR in 
approximately 40%, this increased to approximately 55% when PEG-INF was combined with 
RBV for 48 weeks (228, 229). The SVR rate was higher for HCV genotypes 2 and 3, and 
lower for genotype 1. Treatment in patients with cirrhosis was less effective (230, 231). 
Because of unsatisfactory therapy results in HCV genotype 1 as well as severe side effects, 
new treatment options were needed (232).  
In Sweden at that time, patients with genotype 2 and 3 (and no contraindications) were 
generally offered PEG-INF based therapy, but for patients with genotype 1, therapy was 
recommended only for those with progression of liver fibrosis.  
Over the past decades, increasing knowledge of the HCV lifecycle has revealed several steps 
of the viral cycle that could potentially be new targets for therapy. Understanding of the 
structures of the HCV genome and proteins enabled the design of drugs that led to disruption 
of the viral replication and subsequently a targeted anti-viral therapy for HCV. The two first 
generation protease inhibitors (PI) were marketed in 2011. However, when used as 
monotherapy, resistance mutations developed rapidly, and combination therapy was needed. 
(233). First generation PI therapy plus PEG-INF and RBV increased SVR by 30% in patients 
with HCV genotype 1. This INF-based regimen was associated with an increase of adverse 
events, such as severe anemia, dysgeusia and rash and was contraindicated in patients with 
severe liver cirrhosis.  
In the following IFN-free era with direct-acting antivirals (DAAs), there are four categories 
of drugs according to their therapeutic target: the nonstructural proteins 3/4A (NS3/4A) 
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protease inhibitors (PIs), NS5B nucleoside polymerase inhibitors (NPIs), NS5B non-
nucleoside polymerase inhibitors (NNPIs) and NS5A inhibitors (234). See figure 1 for 
schematic overview of the targets of the DAAs.  
Currently (2016) in Sweden there are restrictions of whom to treat, according to national 
treatment guideline (219, 234, 235):  
 Patients with liver fibrosis stadium 2-4 (F2-F4) assessed by histology or with 
elastography.  
 Patients that have undergone organ transplantations, patients with extrahepatic 
manifestations.  
 Persons planned for IVF 
Choice of DAA treatment regimen is based primarily on the HCV genotype and stage of liver 
fibrosis and the pricing in Sweden. Also, to consider is the risk of evolving viral resistance 
against NS3/4A PIs and /or NS5A inhibitors which may be problematic in the few patients 
who relapse and need re-treatment.  
Tests for assessing resistance to DAAs are now available and could be used, according to 
EASL guidelines, to guide decision regarding therapy (236).  
Therapy with DAAs results in 90-100% SVR after 12 weeks (237-247). The lower SVR rates 
are in patients with advanced cirrhosis and HCV genotype 3, while patients with genotype 1, 
especially genotype 1b, usually achieve SVR in close to 100%. Today, IFN-free regimens are 
primarily recommended in Sweden and in the majority of the Western World (219, 236).  
1.7 HEPATITIS B VIRUS INFECTION AND HBV-HCV DUAL INFECTION   
1.7.1 Hepatitis B 
Hepatitis B virus is a DNA virus and belongs to the Hepadnavirus family. When the virus has 
penetrated into the nucleus of the hepatocyte, the viral DNA exists as a partially double 
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stranded, circular form. The host cell enzymes then aid in several steps resulting in the 
completion of the double stranded DNA and covalently closing of the circle to form a highly 
stable covalently closed circular DNA called cccDNA. During the course of the viral life 
cycle more copies of cccDNA form in the nucleus becoming a stable reservoir of viral 
genetic material within the cell. The cccDNA functions as a mini chromosome, a template for 
the cellular enzyme to produce new pre-genomic messenger RNA (248, 249). The HBV 
cccDNA molecule binds tightly to the histones and other proteins in the nucleus of the 
hepatocyte. This, together with the long half-life of the hepatocyte, contributes to a persistent 
infection (250, 251). The fact that HBV-DNA can integrate into the host DNA might be a co-
factor in the development of HCC in non-cirrhotic liver (252, 253).  
HBV infection is a major public health issue worldwide, with 2 billion people infected, and 
350 million suffering from chronic HBV infection (254, 255). A recent analysis revealed that 
3.6% of the general population globally is chronically infected with the virus (WHO) (255). 
Notification of HBV infected patients has been mandatory in Sweden since 1969. Prevalence 
in the WHO European region was estimated to be 2.1%, ranging from estimated 0.01% in the 
United Kingdom to 10.3% in Kyrgyzstan. Prevalence levels of 10% and above persist in 
some African countries.  
In industrialized countries, rates of new infections and acute disease are highest among young 
adults and transmission predominantly occurs via IDU and high-risk sexual behaviors (256). 
In Asia and Africa, chronic HBV infection is common and usually acquired perinatally or in 
early childhood (257, 258). Sweden is a low prevalent country, the overall HBV prevalence 
has been reported < 5 % and the prevalence of chronic HBV <1% (259-262). Prevalence 
among in individuals originating in high endemic countries was higher, 6.5% (260). The 
trend in Sweden for the last decade has been an increases in chronic HBV and a decrease in 
acute HBV infection(260). 
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The risk of developing chronic HBV infection decreases with age at infection, from about 
90% when infected perinatally up to 6 months of age, to 20–60% between the ages of 6 
months and 5 years and to <5% in otherwise healthy adults (255).  
The natural course of chronic HBV infection is characterized by the interaction between the 
replication of the virus and the immune response of the host and can be separated into phases 
(263-265).  
Initially, chronic HBV infection consists of early replicative phase of chronic hepatitis B 
(CHB), characterized by the presence of hepatitis B e antigen (HBeAg) and high serum levels 
of HBV DNA (referred to as HBeAg-positive CHB) with active liver disease and elevated 
ALT levels. However, the majority of patients will clear HBeAg (and produce anti-HBe 
antibodies) and achieve a state of non-replicative infection, characterized by low or 
undetectable serum levels of HBV DNA and normal ALT levels. 
Perinatally acquired CHB is characterized by a replicative phase and immune tolerance. 
Initially, the HBV replication increases, the hallmark being the presence of HBeAg and high 
levels of HBV DNA in the serum. No clinical symptoms are apparent, the level of ALT is 
normal, and there are no signs of active liver disease (266, 267). This phase can last 10-30 
years. During this time there is low rate of spontaneous HBeAg clearance.  
During second or third decades after infection, transition from the immune tolerance phase to 
immune clearance usually takes place (268). During this phase spontaneous HBeAg 
clearance takes place. This phase is often accompanied with decrease in HBV-DNA and an 
increase in serum ALT, which is believed to be caused by lysis of hepatocytes due to immune 
reaction (269). This immune activation phase is usually followed by a low replication phase 
or inactive carrier state with negative HBeAg and positive anti-HBe. The quantification of 
HBV-DNA and the ALT concentration are low. Significant liver fibrosis is rare in this phase 
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(270). To be categorized as inactive carriers the blood levels of ALT and HBV-DNA need to 
be stable for at least a one year period. 
 
Figure 3. Course of chronic HBV infection 
Patients with a prolonged immune activation phase are at higher risk of liver damage and 
should be considered for treatment of the HBV infection. Decision of antiviral therapy is 
based on assessment of the risk for progressive liver disease, using stage of fibrosis (liver 
biopsy or elastography), blood ALT level and the HBV DNA level to support the decisions 
(271). The antiviral therapies currently recommended for the treatment of chronic HBV 
infection are PEG-IFN for 48 weeks alternatively therapy with one of the nucleoside or 
nucleos(t)ide analogues (NAs), telbivudine, entecavir, or tenofovir for indefinite time (271). 
The available NAs are potent in achieving sustained viral remission, but a total cure is rare, 
due to persistence of transcriptionally active viral cccDNA in the nucleus (271).  
Since 1982, safe and effective vaccines against HBV infection have been available  
1.7.2 HBV-HCV dual infection 
HCV and HBV share a common route of transmission and both are able to induce a chronic 
infection that can lead to fibrosis and cirrhosis and HCC (127). In highly endemic areas, co-
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infection is not uncommon among subjects with high risk of parenteral infection (272). The 
risk of persistence of hepatitis B genome in individuals negative for HBV surface antigen 
(occult HBV) is higher among individuals with HCV infection (273-275). The estimated 
prevalence of HBV-HCV dual infection is 5 to 20 % in HBsAg positive patients and 2-10% 
in anti-HCV positive patients with variable geographic distribution (276). The prevalence of 
dual infection in Sweden is low.  
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2 AIMS  
The overall aim of this thesis was to study morbidity and mortality of individuals with 
chronic hepatitis and of their children. The specific aims were to: 
 To study the association between chronic HBV infection and combined HBV-HCV 
infections and HCC (paper I).  
 To study mortality and cause of death in all individuals with diagnosed HCV 
infection, chronic HBV infection or dual HCV-HBV infections in Sweden (paper II) 
 To study the association between HCV infection in mothers and outcome of their 
pregnancy and birth (paper III).  
 To estimate the mortality of children to mothers with HCV infection. Furthermore, to 
study the cause of death of these children (paper IV).  
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3 MATERIAL AND METHODS      
3.1 THE REGSTRY SETTINGS 
The Swedish personal identification number (PIN) was introduced in 1947, covering the total 
resident population of Sweden. The PIN is unique for all residents and is issued by the 
Swedish Tax Agency at birth when the child is registered in the Census register. A PIN is 
also issued to all immigrants registered in Sweden. The PIN is used in all health care, social 
services, and other authority contacts.  
Statistics Sweden was founded in the middle of the 18th century, derived from old Swedish 
church registers. It has since then been responsible for public statistics regarding decision 
making, debate and research in Sweden. From Statistics Sweden we obtained information on 
duration of formal education and of economical support of the study objects in study III and 
IV. 
A notification of all newly diagnosed HBV and HCV infections to the Public Health Agency 
of Sweden (PHAS) has been mandatory, since 1969 and 1990, respectively. The notifications 
are registered at the PHAS using the personal identification number of the patient. Two 
parallel notifications are made to the PHAS, one from the clinician and the other from the 
laboratory that diagnosed the infection. From the laboratories all results indicating an 
infection are reported, positive HBsAg and » or HBV–DNA, positive HCV antibodies and » or 
HCV–RNA analyses. The clinical notification contains information of epidemiological 
interest if known, such as route of transmission and information regarding whether the HBV 
infection is considered acute or chronic. In the case of an HCV infection, the registration does 
not differentiate acute from chronic.  
3.1.1 The National Tax Board 
The National Tax Board provides dates for emigration and immigration, deaths, and country 
of birth of all Swedish residents. 
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3.1.2 The Swedish Health registers 
The National Board of Health and Welfare (NBHW) is a government agency that holds 
several registers such as the cancer register, the cause of death register, the patient register 
and the medical birth register, among others.  
3.1.2.1 The Cancer register 
Notification of all cancers in Sweden to the Cancer Register has been mandatory for both 
clinicians and pathologists/cytologists since 1958. Required information in the report is the 
site of the tumour, histological type, date of diagnosis, identification number for the tissue 
specimen, and the PIN. Since 2005 the cancers are coded according to the third version of 
International Classification of Diseases for Oncology, ICD-O/3, but all cancer diagnoses are 
also, since 1958, coded according to the seventh revision of the International Classification of 
Diseases (ICD-7). The Swedish Cancer Register is complete and comparable to other quality 
registers in Europe (277). Earlier studies have verified that over 95% of all tumours are 
reported. Furthermore, around 99% have been histologically or cytologically verified (278). 
However, a recent Swedish study demonstrated that 37%-45% of HCC in Sweden were never 
reported to the Cancer register. The reason was probably that fewer cases of HCC were 
histologically verified because of improved non-invasive diagnostic methods, and the 
absence of a histology report resulted in missed cancer reports (139).  
3.1.2.2 The Cause of Death Register 
The cause of death register (DR) contains information on all deaths of Swedish residents 
since 1961. For each death the PIN, sex, date of birth, date of death and the main and up to 19 
underlying causes of death is recorded. The causes of death were coded according to ICD-8 
in 1969-1986, ICD-9 in 1987-1996, and ICD-10 was implemented in 1997. The DR is 
updated every year. Until 2011, the register covered all deceased persons who at the time of 
death were registered in Sweden, regardless of whether the death occurred within or outside 
the country. From year 2012 and onwards all deaths in Sweden were included whether the 
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deceased were Swedish residents or not. The Cause of death is collected from the death 
certificate and is defined as the disease or injury that initiated the chain of disease that finally 
resulted in death. The register has 98-99% completeness (279). Different factors affect the 
completeness of reporting. It seems to be more complete in younger patients and when the 
cause of death is violent(280).  
3.1.2.3 The Swedish National Patient Register 
The Swedish National Patient Register (PAR) contains information on inpatient care since 
1964 (nation-wide since 1987). Psychiatric care was included from 1973. Each in-hospital 
episode is recorded with dates of admission and discharge, surgical procedures, and the 
discharge diagnoses with up to eight medical conditions coded according to ICD. The eight 
revision (ICD-8) was used years 1969-1986, the ninth revision (ICD-9) was used in years 
1987-1996 and the tenth revision (ICD-10) from year 1997. From year 2001, information on 
outpatient visits including day surgery and psychiatric care from specialized outpatient care 
units, are registered in the Outpatient Register. More than 99 % of all somatic and psychiatric 
hospital discharges are included in the in the Inpatient Register. Ludvigsson et al., 2011, 
revealed a high validity for many but not all of the diagnoses. Positive predictive value was 
85%-95% of diagnoses in the register (281). 
3.1.2.4 The Medical Birth Register 
The Swedish Medical Birth Register (MBR) was founded in 1973. It is mandatory for all 
health care providers to report to the register. The number of infants born each year varies 
between 86.000 and 120.000. Information about all births is collected from medical records 
from prenatal, delivery, and neonatal care providers. It includes information on the mothers’ 
previous diagnoses, diagnoses during pregnancies, length of pregnancy, mode of delivery, 
diagnoses of the children and information about various parameters of the children at birth. 
The quality of the register is good. Of all newly born children, 97-99% percent is reported to 
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the register(282). The loss of information over birth is approximately 0.5-3 percent per year 
(283).  
3.2 STUDY POPULATION AND METHODS 
All four studies were register based. The study populations were identified from the national 
surveillance database of HCV and HBV infections at the PHAS. The National Tax Board 
(paper I and II) reviewed the cohorts and excluded all duplicates and notifications with 
incorrect PINs. The Swedish HCV cohort has been well characterized in earlier studies, 
adding data from the Swedish national registers and thus making the cohort very suitable for 
epidemic analysis (135) (284, 285)  
3.2.1 Paper I 
All HBV- and HCV- notifications in the years 1990 to the end of 2004 were identified. In the 
HBV cohort all the notifications for acute hepatitis B and those with HCV co-infection were 
excluded. In addition, all individuals who were reported to have been infected in adulthood 
were excluded. All HBV notiﬁcations were matched with the HCV notiﬁcations from 1990 to 
2004 to identify co-infected individuals. After exclusion of all notiﬁcations of acute HBV 
infection, the remaining ones were included in the HBV–HCV co-infection cohort. The study 
population consisted of two cohorts; the HBV-cohort consisted of 9,646 subjects with chronic 
HBV infection and the HCV-HBV co-infection cohort consisted of 1,697 patients. 
3.2.2 Paper II 
All HBV- and HCV-notifications from years 1990 to 2003 were identified. All notifications 
of acute hepatitis B were excluded. The study population constituted of three cohorts; the 
HCV-cohort consisted of 34,235 individuals reported for HCV-infection (no HBV infection), 
the HBV-cohort of 9,517 individuals reported with chronic HBV infection (no HCV 
infection), and the HCV-HBV co-infection cohort consisted of 1,601 individuals with both 
HCV and chronic HBV-infection.  
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3.2.3 Paper III  
All HCV notifications to the PHAS years 1990-2011 were identified. Identification of all 
childbearing women with HCV infection and their infants was obtained by linking 
information on all women notified with HCV infection to MBR by using their PIN. The 
medical birth register then matched the infants to five controls, i.e. infants of mothers without 
HCV infection. The matching criteria were birth year, gender, county of origin and age of the 
mother. Because of the number of matching criteria, the total (mean) numbers of controls per 
case were only 4.5. The study population constituted of 19,072 infants of 9,599 mothers 
reported with HCV during 1990-2011. They were compared with 86,164 infants of 83,986 
mothers without HCV infection. 
3.2.4 Paper IV 
As in paper III, the study population consisted of all children of women notified with HCV 
infection in the National Surveillance Database at the PHAS years 1990 to 2011. These 
children were matched with five controls, i.e. infants of mothers without HCV infection. The 
matching criteria were birth year, gender, and county of origin and age of the mother. 
Because of the number of matching criteria, the total (mean) numbers of controls per child 
were only 4.5. The study population constituted of 19,097 offspring of 9,599 mothers with 
HCV infection compared with 86,192 children of 83,986 mothers without HCV infection. 
3.3 ANALYSIS 
3.3.1 Paper I 
The study period was 1990-2004. The PINs of individuals in the HBV and HBV-HCV co-
infection cohorts were used to link to the Cancer register. The National Tax Board added 
information on dates of emigration, immigration, deaths, and country of birth.  
To avoid overestimation of the risk due to surveillance bias, the time of observation 
commenced three months after the date of HBV notification for each subject in the HBV 
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study population. For the HCV–HBV co-infection cohort, the observation time commenced 
three months after the date of the second of the two notifications. The observation time 
terminated either at death, the first date of HCC diagnosis reported to the Cancer Registry, or 
31 December 2004, whichever came first. 
Chronic HBV infection in Sweden is mostly found in immigrants from high endemic areas 
(259, 260, 262). 90% of all patients that are infected with HBV during the perinatal period 
develop chronic infection. We therefore stratified the cohort according to age; less than 30 
years, 30 to 39 years, 40 to 49 years , 50 to 59 years, and 60 years and older. Earlier 
epidemiological studies have demonstrated that the HCV-HBV co-infection cohort is similar 
to the HCV cohort in Sweden concerning transmission route. We therefore estimated time of 
infection using a model developed in earlier comparable studies on the HCV cohort (135, 
284). Time from infection was assessed for all routes of HCV infection based on available 
epidemiological data in Sweden (286-288). For transmission route notified as IDU, unknown 
or sexual transmission the year of infection of persons born before 1930 were considered to 
be in 1965; the age of infection in persons born in 1930 were considered to be at the age 35 
years, then falling linearly so when born in 1955 or later they were considered infected at 20 
years of age. We used the age at the time of notification for patients younger than 20 years. 
We approximated the year of infection to be 1980 for persons with transfusion-associated 
HCV infection before blood donor screening was introduced in 1991. Date of notification 
was used as the date of infection for persons with nosocomial and occupational route of 
transmission. We then made three strata depending on the time with infection: infection for 
less than 20 years, infection between 20 and 30 years, and infection for more than 30 years. 
We then assessed the risk of hepatocellular cancer (HCC) in the study cohorts by comparing 
with the general population. The expected number of HCCs was calculated on the basis of 
age, sex, and calendar year-specific cancer incidence rates from the Cancer Register, and the 
observed number of person years in the HBV and the co-infection cohorts. We calculated 
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standardized incidence ratios (SIR) of HCC by comparing the expected incidence with the 
observed HCC incidence. Ninety-five percent exact confidence intervals (CIs) were 
calculated assuming a Poisson distribution of the number of observed cancers.  
3.3.2 Paper II 
The study period was 1990-2003. The PINs of individuals in the HCV and HBV cohorts were 
used to link to the DR. The National Tax Board added information on dates of emigration, 
immigration, deaths, and country of birth.  
For each subject, the observation time started six months after the HBV or HCV notification 
(first notification if co-infected) and ended at death, emigration, or the end of study, 
whichever occurred first. To avoid overestimation of the risk due to surveillance bias from 
HBV and/or HCV infections diagnosed as a result of the disease that led to death, all 
individuals who died less than 6 months after the hepatitis notification were excluded.  
ICD codes according to the main ICD-chapters were used to categorize cause of death in 
main groups. ICD codes of special interest (liver related, drug and alcohol related, external 
reason, HIV, NHL, MM and other malignancies) were then further analyzed. The 
standardized mortality ratio (SMR) was calculated by comparing the mortality in the study 
population with the mortality in the general population. The observed number of deaths was 
divided by the expected number of deaths. The mortality rates for the general population were 
obtained from the DR. For the calculation of the expected number of deaths, the sex and age-
specific mortality rates in the calendar year 1999 were used.  
3.3.3 Paper III 
The study period was 1973-2011. We used relevant ICD codes from ICD-10 (1997-2011), 
ICD-9 (1987-1996) and ICD-8 (1973-1986) for the studied outcomes. Information about pre-
pregnancy diagnoses of the mothers, such as diabetes, hypertension, alcohol and drug use, 
was obtained from both the PAR and the MBR. From Statistics Sweden, we obtained 
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information on the number of years of formal education completed at the time of birth of the 
child, categorized as: less than 9 years, 9 to 12 years, more than 12 years. Country of birth 
was categorized into: Sweden, other Nordic country, non-Nordic European country and non-
European country. Cigarette smoking at any visit to the maternity care was reported as daily 
smoking. Women were categorized by whether they were living with the child’s father, not 
living with the father, or other family situations. Women were categorized as lean if body 
mass index (BMI) at first antenatal visit was 11.0- 19.9 kg/m2, normal weight if BMI was 
20.0- 24.9 kg/m2 , overweight if BMI was 25-29.9 kg/m2 and obese if BMI was 30.0-
60.0kg/m2. Parity was divided into 1, 2 or 3+ children. Data on complications of the 
pregnancy (preeclampsia, gestational diabetes, gestational hypertension), were obtained from 
the MBR.  
Information on outcomes regarding the infant was obtained from the MBR such as Apgar 
score, birth weight and gestational age. Apgar score at 5 minutes after birth was used, 
categorized into 0-6 and 7-10 (used in earlier comparable studies (289)). Gestational age at 
birth was categorized into: very preterm (<32 weeks), moderately preterm (32-36 weeks), and 
term (≥37 weeks). The infants were then categorized if they were small for gestational age 
(SGA). SGA was defined as birth-weight less than two standard deviations (SD) below the 
mean for gestational age based on Swedish reference curve of estimated fetal growth (290). 
Low birth weight was defined as <2500 grams. Gestational age at birth was categorized into: 
very preterm (<32 weeks), moderately preterm (32-36 weeks), and term (≥37 weeks). For 
outcome of interest, relevant ICD codes from ICD-10 (1997-2011), ICD-9 (1987-1996) and 
ICD-8 (1973-1986) was used. Information on malformation was obtained from the MBR and 
from the PAR. Further information on complications at birth, such as cephalohematoma, 
neonatal seizure and intraventricular haemorrhage was obtained from the MBR. Information 
over intrauterine death and postpartum death was obtained from the MBR, which retrieved 
the information from the DR. Stillbirth was defined according to NBHW from 1973, as 
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stillborn after 28 weeks of gestation. In 2008 NBWH changed their definition to stillborn 
after 22 weeks of gestation. Neonatal death was categorized into early neonatal death (within 
6 days) and late neonatal death (7-27 days).  
To investigate the relationship between HCV and the binary outcomes of pregnancy and 
births, adjusted odds ratio (aOR) were calculated through multivariate logistic regression. To 
estimate the association between HCV, gestational age and the Apgar score, adjusted odds 
ratios were calculated with linear regression.  
For the models concerning gestational diabetes, hypertension, preeclampsia, caesarean 
section, still birth, early and late neonatal death, malformation and SGA, the following 
covariates were adjusted for: parity, alcohol use of the mother, drug use of the mother, 
diabetes and hypertension diagnoses prior to pregnancy, smoking, BMI of the mother, 
educational level of the mother and family situation. The covariate was included in the model 
if the interaction effect was more than 10%. P values <0.05 were considered to be statistically 
significant.  
3.3.4 Paper IV 
The study period was 1973-2011. Identification of all childbearing women with HCV 
infection and their infants was obtained by linking information on all the women reported to 
PHAS to the MBR, using their PIN. For this study we used the MBR and the DR. 
Information on outcomes regarding the infant was obtained from the MBR. Gestational age at 
birth was categorized into: very preterm (<32 weeks), moderately preterm (32-36 weeks), and 
term (≥37 weeks). The infants were then categorized if they were SGA. SGA was defined as 
birth-weight less than two standard deviations (SD) below the mean for gestational age based 
on Swedish reference curve of estimated fetal growth (290). Statistics Sweden added 
information on social economical support of the mother and her family at the time of birth.  
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As in paper III, the relevant ICD codes from ICD-10 (1997-2011), ICD-9 (1987-1996) and 
ICD-8 (1973-1986) were used for outcome of interest. ICD codes which constituted the main 
ICD-chapters were used to categorize cause of death. ICD codes of special interest (liver 
related, drug and alcohol related, accidents, Sudden Infant Death Syndrome (SIDS)) were 
then further analyzed. Information on date and cause of mortality of the children was 
obtained from the DR. The baseline characteristics between children of HCV-affected 
mothers (cases) and children of non-affected mothers (controls) were compared by reporting 
absolute and relative frequencies. Differences between the two groups were tested for with 
the chi-square test. 
Survival time was analyzed. The end of follow-up, December 31, 2011, was considered an 
independent censoring event. Crude survival curves in the two groups were calculated with 
the Kaplan-Meier method. Crude and adjusted mortality HRs were estimated with 
proportional-hazard regression models. The crude model included the binary indicator for 
case (0 = control, 1 = case) as the only covariate. The adjusted models also included 
indicators for low gestational age, low birth weight, SGA, and smoking during pregnancy. P-
values less than 0.05 were considered statistically significant.  
3.4 ETHICAL APPROVALS 
For all papers the personal identifiers were removed before the dataset was used for analysis. 
All studies were approved by The Regional Ethical Review Board in Stockholm according to 
the guidelines of the Helsinki Declaration. 
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4 RESULTS  
4.1.1 Paper I 
A total of 15,318 HBV infected patients were reported to SMI between the years 1990 and 
2004. After exclusion of all acute HBV and all HCV co-infected individuals, the HBV cohort 
consisted of 9,464 subjects with chronic HBV-infection. The HBV study population 
contributed to overall 66,768 person-years of observation overall. 85% were born in 1950 or 
later and males accounted for 53%. A total of 76 patients were reported to the Cancer register 
with cancer originated in the liver. Of them, 31 patients were excluded because the cancer 
diagnosis was made before or within three months after the report of the HBV diagnosis. This 
left 45 patients for further risk analysis. The mean time between the HBV notification and the 
cancer diagnosis was 4.8 years. The SIRs are presented in table 1. The lifetime risk of 
developing HCC was estimated to be 10% (95% CI: 6-12) 
Table 1. SIRs for HCC (n=45) in HBV infected patients 
Years with HBV infection Expected Observed SIR 95% CI 
0-29 0.03 1 33 0.9-189 
30-39 0.08 3 38 7-105 
40-49 0.19 9 47 21-89 
50-59 0.35 19 54 33-85 
>60 0.65 13 20 11-34 
Total 1.3 45 35 25-46 
 
There were 3,238 patients reported with co-infection between 1990-2004. After excluding 
those with acute hepatitis B (n=1,850), the co-infection cohort consisted of 1,697 patients in 
the risk analysis. Observation time was 11,392 person-years. A total of 67% were born after 
1950 and males accounted for 78%. In the co-infected cohort, 12 patients were diagnosed 
with HCC and reported to the Cancer register. Two of them were excluded because they were 
diagnosed with HCC within three months from diagnosis of HCV. This left 10 patients for 
further risk analysis. Median age of these patients was 58 years. The standardised incidence 
ratio for the stratum is expressed in table 2. 
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Table 2. SIRs for HCC (n=10) in HBV and HCV co-infected patients 
Years with co-infection Expected Observed SIR 95% CI 
0-19 0.025 0 0 0-150 
20-30 0.118 4 34 9-87 
>30 0.066 6 91 33-198 
Total 0.209 10 48 23-88 
4.1.2 Paper II 
The mean observation times per subject in the HBV cohort was 6.4 years, contributing to 
totally 60,697 person years. Mean age at death was 56 years, 68% were males. The most 
common route of transmission was neonatal transmission (80%). After excluding all 
individuals that died within six months from HBV notification there were 425 (4.5%) deaths. 
The all-cause mortality was significantly increased with SMR 2.3 in the HBV cohort. The 
most frequently underlying cause of death in the HBV cohort was neoplasm. The cause of 
death for all cohorts is presented in table 3.  
The mean observation time of the HCV cohort was 6.3 years contributing to 214,602 person 
years. The mean age at death was 50 years and 77% were men. The most common route of 
transmission was IDU (57%) or unknown (32%). After excluding all deaths within six 
months from HCV notification (n=744) there were 4,651 deaths. The results are presented in 
table 3. The all-cause mortality was significantly increased with SMR 5.8 in the HCV cohort. 
The most frequent underlying cause of death in this cohort was external causes (e.g. injuries, 
intoxication, and suicide) which accounted for 29% of the deaths.  
The mean time of observation in the HCV-HBV co-infection cohort was 7.9 years, in total 
12,667 person years. The mean age at death was 44 years and 85% were male. The most 
common route of transmission was IDU (54%) or unknown (25%). There were 209 (13%) 
deaths in the co-infected cohort after excluding all deaths reported within six months from 
first HBV/HCV notification (n=21). The most frequently reported cause of death was the 
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same as for the HCV cohort or external causes (e.g. injuries, intoxication, and suicide), 34 %. 
The all-cause mortality was also significantly increased in this cohort with SMR 8.5.  
In the HCV and the co-infected cohort, there was an excess risk for death from causes related 
to IDU, e.g. HIV, psychiatric diagnoses (98% drug related) and external reasons, compared 
with the general population. However, the relative risk of liver-related mortality was highly 
increased in all three cohorts. 
Table 3. Cause of death in the HBV, HCV and HBV-HCV cohorts. The risk is expressed as SMR, the 
observed deaths/expected deaths 
 
  HBV (311 deaths) HCV (3,970 deaths) HBV-HCV (188 deaths) 
Diagnosis SMR* 95% CI SMR* 95% CI SMR* 95% cI 
All Cause 2.3 2.0-2.6 5.8 5.6-6.0 8.5 7.3-9.8 
Infection 13.7 8.7-20.6 28.7 25.2-32.5 44.8 25.1-74.0 
Neoplasm 2.8 2.3-3.3 2.8 2.6-3.1 3.9 2.5-5.9 
Blood/immune 6.3 0.8-22.6 30.6 22.6-40.6 19.6 0.5-109.2 
Endocrine 1.8 0.7-3.8 5.6 4.5-6.9 6.6 1.8-17.1 
Psychiatric 3.1 1.8-5.0 15.0 13.7-16.5 26.0 18.0-36.3 
Circulatory 1.4 1.1-1.8 2.6 2.4-2.8 5.1 3.4-7.3 
Digestive tract 5.8 3.8-8.5 15.3 13.8-16.9 16.5 9.0-27.6 
External reasons 1.7 1.2-2.4 12.4 11.7-13.1 11.4 8.8-14.6 
       Subgroups 
      Viral hepatitis 78.9 46.8-124.7 133.0 114.3-153.9 168.6 84.2-301.7 
Liver cancer 31.2 21.9-43.2 34.9 30.1-40.2 65.2 33.7-113.9 
Liver disease 10.7 6.8-15.9 25.1 22.3-28.0 24.4 13.0-41.8 
All liver related 21.7 17.1-27.0 35.5 32.9-38.3 46.2 31.5-62,3 
HIV 11.4 2.4-33.2 41.2 31.4-53.2 23.7 2.9-85.5 
Alcohol,drug related 3.8 2.1-6.4 20.7 18.9-22.7 27.6 19.6-39-6 
*SMR= observed/expected, the expected number of deaths were calculated using age and sex specific 
mortality rates in the general population 
 
All cause SMR related to age showed an excess mortality in all ages, but in the HCV and 
HBV-HCV cohorts the great excess mortality was at age 15-35, then slowly declining. The 
SMR by age showed that the excess mortality from liver related deaths increased with age. 
The maximum liver related SMR was 26 at age 60-69 in the HBV and 42 at age over 70 years 
in the HCV cohort.  
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The liver cancer mortality had the greatest excess risk with SMR 31.2 (HBV), 34.9 (HCV) 
and 65.2 (HBV-HCV). In the HCV cohort risk of death from cancer in lip/mouth, 
oesophagus, pancreas, larynx, lung, cervix uteri and kidney was also significantly increased.  
4.1.3 Paper III 
19,072 births to 9,599 mothers reported with HCV were included and 86,164 births of 83,986 
mothers in whom HCV was never reported.  
Complications of pregnancy are presented in table 4. There was no increased risk of 
preeclampsia, gestational diabetes or gestational hypertension in women with HCV infection. 
There was on the other hand a significantly increased risk of cholestatic liver disease during 
pregnancy. There was also a significantly increased risk of caesarean section in women 
notified with HCV infection compared with women in the general population.  
Table 4. Complications of pregnancy of mothers reported with HCV infection and of mothers of the 
comparison group, presented as Odd Ratio (OR) 
  HCV  
(n=19,072)) 
Non-HCV 
(n=86,164) 
Crude OR Adjusted 
OR 
     
Gestational diabetes P=0.124   1.18 0.88 
No 18,970 85,739     
Yes 111 425     
     
Gestational hypertension P=0.218   1.15 1.03 
No 18,985 85,787     
Yes 96 377     
     
Preeclampsia P=0.846   0.94 0.6 
No 19,070 86,111     
Yes 11 53     
     
Cholestatis of pregnancy P=<0.001   4.88 4.78 
No 18,885 85,981     
Yes 196 183     
     
Fetal distress P= 0.250   1.66 1.09 
No 19,074 86,154     
Yes 7 19     
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The pregnancy outcome is presented in table 5. The mean Apgar score after 5 minutes was 
significantly lower in infants to HCV-infected mothers compared to the comparison group. 
The mean difference in gestational age was also significantly lower in cases. The pregnancy 
of the mothers with HCV infection was at higher risk of terminating in stillbirth and there 
was also a significantly higher risk of late neonatal death than in the comparison group. 
Furthermore, we found an increased risk of neonatal seizure. There was neither increased risk 
of malformations nor of cephalohematoma, ventricle hemorrhage or fetal distress in the 
infants born to HCV infected mothers. 
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Table 5.  Pregnancy outcomes of mothers reported with HCV and of mothers of the comparison 
group, presented as Odds Ratio (OR)  
  
HCV 
(n=19,072) 
Non-HCV 
(n=86,164) Crude OR Adjusted OR 
     
Cesarean section P< 0.001   1.33 1.31 
No 16,166 7,5907     
Yes 2915 10,257     
     
Small for gestational age P<0.001   1.55 1.64 
No 17,495 81,200     
Yes 885 2,657     
Missing 701  2307     
     
Stillbirth P<0.001   6.62 7.03 
No 18,934 86,063     
Yes 147 101     
     
Early neonatal death (1-6d) P=0.135   1.31 1.41 
No 19,041 86,026     
Yes 40 138     
     
Late neonatal death (7-27d) P=0.005   1.91 1.78 
No 19,054 86,100     
Yes 27 64     
     
Neonatal seizure P<0.005   2.26 1.3 
No 19,053 86,132     
Yes 28 32     
4.1.4 Paper IV 
Overall, there were 438 (2.3%) deaths amongst the cases of 19,097 children to mothers with 
HCV infection, and 961 (1.1%) deaths in the comparison group.  
Out of 438 deaths in total, 176 (39%) died in the first year of life, 110 (25%) at the age 1 to 
20 years, 152 (34%) died between age 21 and 40 years. Out of the children, there were 688 
that were reported with HCV to the PHAS. Of those were 127 individuals reported with HCV 
before the age of 2 years. In the comparison group, 241 individuals were reported with HCV 
during the study period. One of them was reported before the age of 2 years (p<0.005). 
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At infant up to one week of age, the mortality HR was 1.41 (95% CI 1.09-1.82) but when 
adjusted for low gestational age, low birth weight, SGA and smoking, the mortality HR was 
0.98 (95% CI 0.73-1.31). From 1 to 4 weeks, the adjusted HR was 2.26 (95% CI 1.37-3.74, 
p<0.05) and from 1 to 6 months it was 2.63 (95% CI 1.88-3.69, p<0.05). Between the ages of 
6 months to 15 years, there was no significant difference in mortality. Figure 4 shows the 
survival curves in the study population and the comparison group. 
 
Figure 4. Crude survival curves in the two groups with the Kaplan-Meier method 
Red line: Offspring of mothers with HCV infection 
Green line: Offspring of mother without HCV infection 
 
Children of HCV infected mothers died twice as often from sudden infant death syndrome 
(SIDS), older children died 1.6 times as often from accidents, and 2.7 times as often from 
drug associated deaths compared to the comparison group. There was no difference in cause 
of death by liver disease. Out of 129 of the children of HCV infected mothers that died of 
accidents, 65% were over the age of 21 years. All were over 1 year of age. After year 1995, 
death from SIDS was reduced in both cohorts. It was still more frequent in the HCV group 
compared to the comparison cohort.  
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5 DISCUSSION 
5.1 METHODS AND STUDY DESIGN:  
All the studies included in this thesis were register-based cohort studies. A cohort is a defined 
group of individuals followed for a period of time and can be defined by exposure, a specific 
experience or other specific characteristics. Such a cohort can then be compared to an 
unexposed population to investigate if there is an association between the exposure and the 
studied outcome. Cohort studies are well suited for rare outcomes, and can be performed 
using register data. In the current studies the exposure was mostly HCV but also hepatitis B 
and HCV and HBV co-infection. These cohorts were compared with the general population. 
The outcomes were HCCs, perinatal complications and mortality, which we studied using 
national registries.  
To estimate the association between the virus infection and HCC in the first paper, the 
expected number of HCC was calculated on the basis of age, sex and calendar year-specific 
cancer incidence rates from the Cancer Register and the observed number of person years by 
age group and sex in the hepatitis cohorts. In the second paper, the association between 
hepatitis and various causes of death was analyzed by comparing the mortality of the hepatitis 
cohorts with the mortality of the general population by sex, age and calendar year-specific 
(year 1999) mortality rates of all diagnoses of interests. In paper 3, the association between 
HCV infection in mothers and various obstetrical and neonatal outcomes were investigated 
by comparing them with groups of five children matched by mother’s age at birth, calendar 
year at birth, gender and county of birth and using aOR. Same method matching was used in 
paper 4 to assess of the association between HCV infection in mothers and the mortality of 
their offspring using HR.  
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Systematic errors 
When studies are designed, attempt is always made to reduce potential systematic and 
random errors. Systematic errors are not affected by the size of the study population. 
Systematic errors are classified into three broad categories: selection bias, information bias 
and confounding.  
Selection bias occurs when the association between exposure and disease differs for those 
individuals who participate and those who do not participate in the study. 
 In all papers in this thesis individuals reported with HCV and/or HBV infection during a 
specific period of time were included. In paper I an attempt was made to avoid selection bias 
of the HBV cohort by excluding individuals reported with acute HBV and all those reported 
with HBV infection in adulthood. Individuals presenting with HCC within three months after 
HBV notification were excluded from the analysis. This was done in order to minimize the 
effect of selection bias related to individuals being diagnosed with HBV at the time of the 
HCC diagnoses. In paper 2, the same approach was used; all individuals who died within six 
months after HCV and/or HBV notification were excluded. The exposed group may include 
people that were diagnosed and notified but then either had spontaneously cleared the 
infection or been treated and cured. This could certainly cause a selection bias and 
underestimation of the relative risk in all studies. In the unexposed group, there could be 
individuals with undiagnosed HCV or HBV infection or even individuals with HBV 
diagnosed before year 1990. but we believe these are only a few individuals that might 
somewhat dilute the results (291). It is estimated that approximately 99.1% of all diagnosed 
HBV and 99.5% of HCV infection are reported to the PHAS in Sweden, 
Information bias occurs when information collected from or about the studied subject is 
incorrect. This can lead to the studied individual being placed in the incorrect category. 
Misclassification can be generalized or similar for both exposed and non-exposed groups and 
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thus are non-differential. If the information bias is related to exposure or outcome the 
misclassification becomes differential, thus differs in the exposed and unexposed group.  
The diagnosis of chronic HBV and HCV infection is mainly based on random testing and 
screening of individuals at risk but both the physician and the laboratory are obliged to notify 
the infection to the PHAS since year 1990.  
Misclassification of outcome may have occurred in our studies. In the Swedish Cancer 
register, it is estimated that 95% of all tumors diagnosed are reported and approximately 99% 
are verified histologically (278, 292). Two different radiological examinations for the 
diagnosis of HCC are required. Histological examination is however not required. In paper 1, 
53 of 55 HCC were histologically verified. High sensitivity and specificity  is established of 
specific diagnoses in the DR (279).  
For registered diagnosis codes in the MBR and the PAR, misclassification of outcome could 
have occurred in both exposed and unexposed group. The same could apply to registered 
causes of death in the DR. In the current studies it could be argued that the potential 
misclassification might be similar in both exposed and un-exposed cohorts thus driving the 
difference in effect to null value.  
Confounding 
Confounding is a central issue for epidemiologic study design. Confounding is a factor that is 
closely associated with the exposure and a potential risk factor for the outcome. There are 
ways to modify a cohort study design to control the confounding variables.  
Restriction is when a selection is made of subjects who have the same values for a 
confounder thus neutralizing the effect of the confounding in the outcome.  
If a factor is suspected of being a possible confounder, a stratification of that factor could be 
used, for example, to stratify association between exposure and outcome per age group.  
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In paper 1, the risk of developing HCC in time/age intervals was stratified on estimated 
infection duration, thus controlling the effect of time on the development. In paper 4 the 
stratification of the risk regarding outcomes by route of infection was considered, but due to 
the large number of underreported and unknown route of infection, we chose not to do it.  
Matching is a way to minimize the effect of confounding in cohort studies. Even though it is 
used to increase precision in studies, it should be used carefully as matching by more than 
one variable can introduce bias. In paper III and IV, 5 controls were selected from the 
background populations and matched by gender, year of birth, age of mother at birth and 
country of residence. It is probably preferable to have more than one control in the study to 
obtain a larger sample size to increase the precision of the results. Overall, 5 controls for 
every case were aimed for and resulted in 4.5 controls for every case.  
If a confounder cannot be controlled in the study design, it is possible to control it through 
multivariate analysis which can potentially lead to more reliable results. There are 
confounders that are difficult to control because of information bias, when the patients e.g. do 
not disclose their use of illicit drugs when they visited the midwife. Well-known confounders 
are illicit drug use, alcohol consumption and smoking, which may have affected results in our 
studies. In paper III we attempted to adjust for these factors by linking to the patient register 
for all diagnoses revealing drug and alcohol abuse up to the date of birth.  
In paper III, in which the outcomes gestational diabetes, hypertension, preeclampsia, 
caesarean section, still birth, early and late neonatal death, malformation and SGA were 
analysed, adjustment was made for the covariates: parity, alcohol use of the mother, drug 
abuse of the mother, diabetes and hypertension diagnoses prior to pregnancy, smoking, BMI 
of the mother, educational level of the mother and family situation. The covariate was 
included in the model if the interaction effect was more than 10%. We did not adjust for low 
 57 
birth weight or short gestation, since according to our judgement it is in the causal pathway of 
the outcome.  
In paper IV, models were used to adjust for low gestational age, low birth weight, SGA, and 
smoking during pregnancy primarily to explore the association between HCV infection of the 
mothers and SIDS. When considering the increased frequency of death by drugs abuse and 
alcohol overconsumption and accidents in teenage children of mothers with HCV infection, 
confounders might exist such as mother’s drug  abuse, poor social situation in relation to the 
mother’s substance abuse, inherited behavior (drug abuse) and maybe inherited psychiatric 
diagnoses that we could not control for in the current studies (293). Further studies could 
explore the importance of these factors.  
Random Error 
Statistics are used to estimate the association between exposure and outcome after correction 
for confounding and to assess variability in the data. The goal of the analysis must be to 
obtain the most accurate results with minimal error.  
Confidence interval (CI) consists of collected values around the estimated result indicating 
the quantity of random error in the estimate. A wide CI indicates a low precision in contrast 
to narrow CI indicating a high precision of the results. The size of the sample is one of the 
most important factors that determine the width of a CI. In our studies, we had a large sample 
size due to national registry cohorts and a long follow up time, generally generating narrow 
CIs, with high precision.  
External and internal validity 
Did our studies measure what was intended to be measured? Is the association between 
exposure and outcome properly demonstrated? In the absence of biases, confounding and 
random error it is stated that validity is high.  
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The ability to generalize our findings to other populations than the one studied is called 
external validity. In our studies we used participants with reported HCV and HBV infection 
and the children of women with HCV infection in Sweden. Our findings can only apply to 
HCV and HBV infected individuals. Confounding factors have been discussed above.  
5.2 FINDINGS AND IMPLICATIONS 
5.2.1 Hepatocellular carcinoma 
This study demonstrated high risk for HCC in the HBV infected cohort after estimated 30 
years of infection and in the HCV-HBV cohort after estimated 20 years of infection, 
compared to the general population in a low endemic area.  
In the HBV cohort the relative risk for HCC gradually increased until it reached peak in the 
strata 50-59 years. A numerical decrease of SIR was then noticed after 60 years of infection. 
This may indicate that the most susceptible individuals have already developed their cancer 
by that time or perhaps the individuals in this stratum are under-diagnosed due to old age. 
High incidence in older ages is also expected in the general population and therefore could 
also explain the decrease in the relative risk in the stratum over 60 years of infection.  
In the HBV-HCC co-infection cohort, the overall relative risk for developing HCC was 48 
times elevated. Epidemiological studies on interaction between HBV and HCV infection 
have not been consistent. Earlier meta-analysis have demonstrated synergism or additive 
(supra-additive or even multiplicative) risk ratios of co-existence of the two viruses in HCC 
(140, 294). However a more recent meta-analysis presented a subadditive risk of the two 
viruses for HCC (141). Compared to a Swedish study on HCC among HCV infected 
individuals in Sweden the current study presented a numerically higher risk of developing 
HCC in dual infection compared to mono infection with either HBV or HCV indicating that 
there is an interference between the two viruses in the carcinogenic process (135). We could 
however not confirm this significantly because of too few HCC cases.  
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According to existing literature and to our findings, individuals with CHB and HBV-HCV 
dual infection are in excessive risk of developing HCC during their lifetime. The current 
study confirms that the HCV cohort and HBV-HCV cohort have the same characteristics and 
probably share the same hazardous lifestyles. These results might therefore support the 
decision and the Swedish Clinical guidelines and EASL to vaccinate individuals with 
confirmed chronic HCV against HBV to decrease the rate of cirrhosis and its complications 
(HCC) secondary to dual infection. (145). 
5.2.2 Hepatitis C and/or B infection and mortality 
The current national cohort study demonstrated that individuals with HCV and/or HBV 
infection had an excess risk of mortality from almost all diagnoses. The all-cause mortality in 
the HCV- and the co-infection cohorts was highest in the younger age group (15-35years). As 
noticed in paper I the HCV and HCV-HBV co infection cohorts consisted of a large 
proportion of people who inject drugs (PWIDS) either earlier or actively, often with 
concomitant alcohol use. This might be reflected in the high risk of death in younger ages 
from causes such as injuries, intoxication, suicide and external causes. This indicates that 
intravenous drug use and the associated lifestyle might be a larger threat than HCV infection 
in young drug addicts. Same trend was seen in the children of the women in the HCV cohort 
in paper IV, where there was an increased mortality after the age of 16 due to accidents and 
drug and alcohol abuse.  
The HBV cohort consists mainly of individuals infected at birth or at early age in high 
endemic areas, as discussed earlier. The all-cause and liver related death in Sweden was very 
similar to these high endemic areas (254).  
Mortality due to liver related causes was increased in all cohorts. The SMR due to liver 
related mortality gradually increased with age. The more prominent increase in the HCV and 
the co-infection cohort might be explained by concomitant alcohol induced disease. However 
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when the subgroup with HCV transmission via blood transfusion and the HBV cohort was 
analyzed where the increase in mortality due to psychiatric causes was less prominent, the 
SMR revealed increased death rates due to liver related causes as well.  
The SMR due to HCC was increased in all cohorts 31, (HBV), 35 (HCV) and 65 (HCV-
HBV). The excess SMR in the co-infection cohort could be explained by a synergy between 
the two viruses as discussed earlier.  
The increased risk of death from congenital disease, genitourinary disease and renal failure 
reflects increased mortality due to underlying disease, which in turn by blood transfusion and 
hemodialysis results in the HCV transmission.  
Increased mortality due to diabetes mellitus (DM) related causes in the HCV cohort were 
noticed. The association between DM and HCV has been described in earlier studies(295). 
This is in agreement with paper III, where the cohort of HCV infected mothers had 
significantly more often diabetes diagnoses before pregnancy compared with the general 
population. 
 Large proportion of the HCV and/or HBV cases were notified within 6 months of deaths that 
were due to lethal complications of the HCV and/or HBV infection. As discussed earlier the 
virus infection has a long lag time and can go unnoticed for decades until it presents in the 
terminal stages of the disease.  
This study demonstrated and that all cohorts were at increased risk of mortality compared to 
the general population. The interaction of HCV-HBV Co-infection seems to entail increased 
mortality due to most causes of death. Attention should also be given to young individuals 
infected with HCV and their lifestyle for preventive interventions. In the light of the DAAs 
more effective screening in early stage of the disease is needed in risk groups with the aim of 
treatment before advanced liver disease develops.  
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5.2.3 Hepatitis C infection and pregnancy 
Our study demonstrated that pregnancy in HCV infected women is associated with negative 
maternal and neonatal outcomes.  
The present study demonstrated an increased risk for caesarean section in women with HCV 
infection compared to women in the general population. This might reflect different 
obstetrical management due to HCV infection but concern for adverse pregnancy outcomes 
and failed labor might be the most probable reasons. Concomitant HIV infection is also an 
indication for caesarean section, but after excluding HIV co-infected mothers from the 
analysis there was still an increased risk of caesarian section among HCV mono-infected 
women.  
The study confirmed that women notified with HCV infection had increased rate of DM and 
diagnosis before birth. The association of HCV infection and DM has been described in 
several studies (154, 187, 296). Furthermore the study showed an increased risk for 
hypertension diagnosis before birth. One explanation might be that these women seek 
medical care more often because of co-morbidities and therefore get diagnosed earlier 
compared to the general population. 
There was an increased risk of cholestatic liver disease during pregnancy (ICP). Risk factors 
for the development of ICP have been described. Several studies have shown a highly 
significant increase of ICP in women with HCV infection (173-175). Other have 
demonstrated that HCV infection is more prevalent in women with ICP (176). The etiology 
behind that is not clear. But several theories exist(171) 
The present study demonstrated that infants born to HCV infected mothers were at significant 
risk of both preterm birth and being SGA. Earlier studies are in agreement with these results 
(297, 298). Proposed explanation might be through immunologic mechanisms. natural killer 
T (NKT) cells have been shown to be important for clearance of HCV in acute infection 
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(190). Hurtado and her group established that placental HCV infection increased cytotoxicity 
of NKT cells (191). This might explain the adverse birth outcomes in the HCV infected 
mothers as the infection of the virus induced NKT cytotoxicity which produces cytokines and 
stimulates the innate immune response in the mother, and thus contributes to placental 
damage, intrauterine growth restriction, perinatal mortality and preterm labor. A viral 
infection of the mother induced production of inflammatory cytokines and thus activated the 
maternal immune system that in turn caused placental damage, fetal mortality and preterm 
birth (192). If this process does not terminate the birth it might sensitize the mother to other 
infections and promote inflammation in the fetus (193). 
The increased risk for preterm birth might also be explained by co-factors of the mother such 
as drug abuse and alcohol overconsumption. To minimize the effect of these co factors, 
adjustments were made for smoking, earlier drug use and alcohol use.  
Increased risk of neonatal seizures was also demonstrated. This might in part be explained by 
neonatal abstinence syndrome in the children of mothers with active drug abuse. It is however 
of interest that there is a known biological basis for the association of HCV infection and 
neurological dysfunction in adults (157). The current findings are partially in accordance to 
results obtained by Salemi et al., who found borderline increase in neonatal seizures (299).  
The current study demonstrated an increased risk for still-birth in women with HCV infection 
when compared to the general population. This might also have a multifactorial cause, being 
both attributed to the mother’s abuse and influenced by the HCV inflammation. Studies 
evaluating intrauterine death have been contradictory, several have demonstrated no risk 
while other have demonstrated increased risk of spontaneous abortion mostly in acute 
hepatitis (297, 300). Advanced liver disease is a reported risk factor for perinatal death of 
infants (301, 302). Information about prior cirrhosis diagnosis of the mothers in the study was 
not obtained. This is however a rare occurrence. The risk of late neonatal death was also 
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significant. Reported data over neonatal mortality is lacking. The cause of deaths and 
potential mechanisms behind the increased risk of stillbirth and neonatal death needs to be 
explored in further studies.  
The current study demonstrated that women with HCV are in increased risk of several 
adverse pregnancy outcomes. There was an excessive risk of perinatal mortality among 
infants to women with HCV infection. This might suggest that all women should be screened 
for HCV infection at the first neonatal visit. All women diagnosed and notified with HCV 
should be carefully monitored during pregnancy and birth. Women of fertile age might 
benefit from treatment for HCV infection with the aim of cure before pregnancy.  
5.2.4 Survival of the offspring 
Offspring of mothers with HCV infection had a significantly increased mortality rate 
compared to the children in the general population the first six month of life.  
The study indicates that the most common cause of death was SIDS in infants less than 6 
months of age. SIDS is one of the leading causes of death in infants (303, 304). Known risk 
factors for SIDS are smoking during pregnancy, preterm birth, metabolic abnormalities and 
malformation in the child (303). Earlier studies have also implicated drug use (methadone) 
during pregnancy as a risk factor (305). The incidence of SIDS has decreased in 
industrialized countries, including Sweden, since 1992 when the advice of change in sleeping 
positions of infants was issued. Our study shows that the number of SIDS decreased after 
1995 in both cohorts, although it was still more frequent in children of HCV mothers. The 
mechanism of SIDS is not fully identified. Proposed mechanism might be HCV mediated 
injury during pregnancy although, parents that are noncompliant to the abovementioned 
advice is also plausible.  
The mortality rate increased again after the age of 16 years. The study indicated the mortality 
was related to accidents and due to alcohol and drugs use. Same trend was seen in the HCV 
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cohort in paper II. Studies that have looked into cause of accidents in young adults have 
indicated that attention deficit hyperactivity disorder, insomnia and drug abuse and alcohol 
are possible risk factors (306-308). The impact of the maternal drug abuse probably being an 
important factor concerning alcohol and drug use in the children. A recent Swedish study 
demonstrated the influence of both genetic and parental factors contributing substantially to 
offspring tendency for drug abuse (293). This could in part be supported by the fact that 3% 
of the children of HCV infected mothers were reported to PHAS with HCV infection. This is 
significantly higher than in the general population. Information regarding co-morbidity of the 
children was not included in the study.     
This study demonstrated that the offspring of women with HCV infection are at excessive 
risk of premature death, with significantly increased risks during the first six months after 
birth and in young adults. Mothers with HCV infection and their children should be carefully 
monitored with focus on the first six months of life to prevent premature deaths. Attention 
should also be given to their teenagers and their lifestyles, for preventive interventions.  
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6 IMPLICATIONS FOR FUTURE STUDIES 
On the basis of the results of paper I- IV the following is of interest: 
 To do a nationwide cohort study to analyse the association of HCV infection in 
mothers and morbidity in their children born after 1996. 
 A prospective study of the outcome of pregnancy in HCV infected women. This 
should include clinical information about viremia, treatment (DAAs), co-morbidities, 
drug and alcohol abuse, smoking habits of the mother, and the HCV transmission rate 
with emphasis of perinatal morbidity and mortality.Data from regular monitoring of 
the fetus should be obtained in collaboration with a neonatolog and a obstetrician. 
This would further enhance our knowledge about pregnancy outcome in these women 
and the effect of treatment on the outcome.  
 A prospective study of the children to mothers with HCV and HBV, including 
information about virus transmission, therapy of the mother, drug abuse, alcohol 
abuse, smoking habits of the mother and co-morbidities of the mother and the infant. 
This would further increase our understanding of the risk factors associated with the 
increased neonatal mortality in these children.  
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7 CONCLUSIONS 
This thesis includes national register-based cohort studies of morbidity and mortality in 
children born to mothers with HCV infection and in patients with HCV and HBV infection in 
Sweden. The main conclusions are:  
 There is a highly increased risk of HCC in individuals with chronic HBV infection 
and with HBV and HCV co-infection, when compared with the general population.  
 All-cause mortality was significantly increased in the three cohorts of HBV, HCV and 
HCV-HBV co-infected. Liver-related mortality was highly increased in all three 
cohorts, especially after the age of 50 years.  A large proportion of the HCV and/or 
HBV infections were notified within 6 months before death due to lethal 
complications. More effective screening to diagnose infection at an early stage is 
needed in risk groups with the aim to treat before complications such as cirrhos and 
HCC arise.  
 In the HCV and HBV-HCV cohorts there was a high risk of lifestyle related mortality 
in relation to drug use, especially in young adults. Drug prevention intervention is 
needed for this groups.  
 Pregnant women with HCV infection had an increased risk of adverse pregnancy and 
neonatal outcome. Screening for HCV should be considered to identify pregnant 
women with HCV. They should be carefully monitored through pregnancy and birth.  
 An excessive perinatal mortality in infants of women with HCV infection was 
demonstrated. The cause of this is unclear and needs more research.  
  Mortality was highly increased the first six month of life in the children of mothers 
with HCV infection. Our data indicated  that SIDS was the main cause. Known risk 
factors for SIDS should be removed and the parents instructed to take measures to 
prevent SIDS.  
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 Mortality in children of mothers with HCV infection is significantly increased after 
age of 16, mostly due to drug and alcohol related causes and accidents. Mothers with 
HCV infection were often infected through IDU, which might increase the risk of 
drug use in their adolescent children. Awerness and sometimes intervention is needed 
for these children.  
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